Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00234429
Status:
COMPLETED
Last Update Posted:
2007-12-18
First Post:
2005-10-05
Brief Title:
A Phase 2 Study of Tomudex Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomized Placebo-Controlled Double-Blind Phase 2b Study of Raltitrexed Tomudex and ZD1839 Iressa Versus Raltitrexed Alone as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to compare the activity of raltitrexed and ZD1839 versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by estimating progression free survival PFS in each treatment arm
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None